AbbVie Total Long Term Liabilities 2010-2024 | ABBV
AbbVie total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
- AbbVie total long term liabilities for the quarter ending September 30, 2024 were $94.289B, a 5.56% increase year-over-year.
- AbbVie total long term liabilities for 2023 were $86.473B, a 5.99% decline from 2022.
- AbbVie total long term liabilities for 2022 were $91.98B, a 4.09% decline from 2021.
- AbbVie total long term liabilities for 2021 were $95.899B, a 11.86% decline from 2020.
AbbVie Annual Total Long Term Liabilities
(Millions of US $) |
| 2023 |
$86,473 |
| 2022 |
$91,980 |
| 2021 |
$95,899 |
| 2020 |
$108,807 |
| 2019 |
$81,702 |
| 2018 |
$50,559 |
| 2017 |
$49,048 |
| 2016 |
$51,682 |
| 2015 |
$38,211 |
| 2014 |
$14,378 |
| 2013 |
$17,827 |
| 2012 |
$16,869 |
| 2011 |
$1,692 |
| 2010 |
$1,670 |
| 2009 |
$ |
AbbVie Quarterly Total Long Term Liabilities
(Millions of US $) |
| 2024-09-30 |
$94,289 |
| 2024-06-30 |
$93,201 |
| 2024-03-31 |
$99,305 |
| 2023-12-31 |
$86,473 |
| 2023-09-30 |
$89,319 |
| 2023-06-30 |
$90,230 |
| 2023-03-31 |
$93,651 |
| 2022-12-31 |
$91,980 |
| 2022-09-30 |
$92,586 |
| 2022-06-30 |
$94,025 |
| 2022-03-31 |
$94,376 |
| 2021-12-31 |
$95,899 |
| 2021-09-30 |
$106,748 |
| 2021-06-30 |
$106,694 |
| 2021-03-31 |
$104,817 |
| 2020-12-31 |
$108,807 |
| 2020-09-30 |
$110,151 |
| 2020-06-30 |
$110,152 |
| 2020-03-31 |
$82,143 |
| 2019-12-31 |
$81,702 |
| 2019-09-30 |
$50,174 |
| 2019-06-30 |
$48,767 |
| 2019-03-31 |
$50,691 |
| 2018-12-31 |
$50,559 |
| 2018-09-30 |
$53,698 |
| 2018-06-30 |
$47,792 |
| 2018-03-31 |
$48,731 |
| 2017-12-31 |
$49,048 |
| 2017-09-30 |
$49,120 |
| 2017-06-30 |
$48,726 |
| 2017-03-31 |
$51,822 |
| 2016-12-31 |
$51,682 |
| 2016-09-30 |
$51,054 |
| 2016-06-30 |
$52,299 |
| 2016-03-31 |
$38,415 |
| 2015-12-31 |
$38,211 |
| 2015-09-30 |
$41,156 |
| 2015-06-30 |
$37,093 |
| 2015-03-31 |
$14,272 |
| 2014-12-31 |
$14,378 |
| 2014-09-30 |
$17,174 |
| 2014-06-30 |
$17,510 |
| 2014-03-31 |
$17,744 |
| 2013-12-31 |
$17,827 |
| 2013-09-30 |
$17,800 |
| 2013-06-30 |
$17,547 |
| 2013-03-31 |
$17,446 |
| 2012-12-31 |
$16,869 |
| 2012-09-30 |
$1,693 |
| 2012-06-30 |
$1,365 |
| 2012-03-31 |
$1,396 |
| 2011-12-31 |
$1,692 |
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
$1,670 |
| 2009-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$294.353B |
$54.318B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
